Does timing of tocilizumab administration affect mortality in COVID-19? A Scottish multicentre retrospective cohort study.

ABSTRACT:

Background

The optimal timing of tocilizumab treatment during the disease course of COVID-19 has yet to be adequately defined in the context of randomised controlled trials and the effect of tocilizumab on real-world populations remains unclear. We examined the effect of different timing of tocilizumab, on mortality, in a cohort of adults with COVID-19.

Methods

All adults (≥18 years old) with confirmed COVID-19 admitted to four hospitals in the West of Scotland between 8 January 2021 and 31 March 2021 and who received tocilizumab were included in a retrospective observational cohort study. Patients were assigned to either an early (day of admission or first day after admission) or late (days 2-7 of admission) cohort based on tocilizumab initiation. The primary outcome was 90

SUBMITTER: MacGregor F 

PROVIDER: S-EPMC11367351 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature